# Unveiling the common mechanisms and therapeutic targets of medicinal herbs in acute pancreatitis: a network pharmacology and experimental validation approach

**Authors:** Yuxin Shi, Yan Jia, Ya Liu, Hanyue Wang, Honghui Liu, Yilin Huang, Peiyan Chen, Jie Peng

PMC · DOI: 10.1186/s40643-025-00925-1 · Bioresources and Bioprocessing · 2025-07-30

## TL;DR

This study identifies linarin and the PI3K/AKT pathway as potential treatments for acute pancreatitis using network pharmacology and experiments.

## Contribution

The study reveals linarin and AKT1 as novel therapeutic targets for acute pancreatitis through network pharmacology and experimental validation.

## Key findings

- Linarin showed strong binding affinity with AKT1 and other targets linked to acute pancreatitis.
- In vivo and in vitro experiments confirmed linarin's protective effects against pancreatic damage.
- The PI3K/AKT pathway was validated as crucial for linarin's therapeutic mechanism.

## Abstract

Acute pancreatitis (AP) is an acute abdominalgia with complicated pathogenesis and high mortality, which is lacking in specific means for clinical diagnosis and treatment. Currently, numerous traditional Chinese medicines have demonstrated remarkable efficacy in AP. Given their multi-target and multi-compound actions, we hypothesize that an underlying common mechanism may contribute to their therapeutic effects. This study aimed to identify key therapeutic targets and potential strategies for AP by investigating the shared pharmacological effects of medicinal plants through network pharmacology analysis and experimental validation.

We systematically searched the literature for medicinal herbs that have been reported in AP treatment. Next, we utilized the TCMSP database to identify active compounds that were present in at least two medicinal herbs. Key active compounds and targets were determined through Cytoscape analysis and a PPI network, followed by KEGG pathway enrichment analysis. Combined the core targets identified by Cytoscape and the targets enriched in the PI3K/AKT signaling pathway, molecular docking was performed to assess the binding affinity between the intersecting targets and active compounds. Finally, high-affinity compounds were screened, and linarin’s optimal binding profile led to its selection for further in vivo and in vitro experimental validation.

A total of 37 medicinal herbs were retrieved from the literature search. We identified 62 common compounds and 968 targets from medicinal herbs, further taking intersection to 319 targets for anti-AP. Based on this, “compound-target” and “target” networks were constructed, and the top 12 key active compounds and 11 targets were selected. KEGG analysis indicated that the PI3K/AKT pathway might be closely related to pancreatic protection. Molecular docking results showed that linarin exhibited good binding affinity with all core intersecting targets, particularly with AKT1. Subsequently, both in vivo and in vitro experiments demonstrated that linarin could alleviate AP-induced pancreatic damage and systemic inflammation. To further validate the mechanistic involvement of PI3K/AKT signaling pathway, we employed the PI3K/AKT activator 740 Y-P, which was found to effectively reverse linarin-mediated downregulation of PI3K/AKT activation, thereby confirming the crucial role of this pathway in linarin’s protective effects.

Exploring therapeutic strategies based on common mechanisms and targets may be an effective approach. This study revealed that linarin and AKT1 were potential therapeutic compounds and targets for AP in the preclinical stage, which could provide theoretical support and new insights for the drug discovery of AP.

The online version contains supplementary material available at 10.1186/s40643-025-00925-1.

## Linked entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207]
- **Chemicals:** linarin (PubChem CID 5317025), 740 Y-P (PubChem CID 90488730)
- **Diseases:** acute pancreatitis (MONDO:0006515)

## Full-text entities

- **Genes:** Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 25125], Map1lc3a (microtubule-associated protein 1 light chain 3 alpha) [NCBI Gene 362245] {aka LC3-I, LC3-II, LC3A}, Lipg (lipase G, endothelial type) [NCBI Gene 291437] {aka lipase}, Myd88 (MYD88, innate immune signal transduction adaptor) [NCBI Gene 301059], Jun (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 24516], Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Tmprss11d (transmembrane protease, serine 11d) [NCBI Gene 231382] {aka AST, AsP}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Gpt (glutamic pyruvic transaminase, soluble) [NCBI Gene 76282] {aka 1300007J06Rik, 2310022B03Rik, ALT, ALT1, Gpt-1, Gpt1}, Casp3 (caspase 3) [NCBI Gene 25402] {aka CPP32-beta, Lice, Yama}, Apcs (amyloid P component, serum) [NCBI Gene 29339] {aka Sap}, Becn1 (beclin 1) [NCBI Gene 114558] {aka Beclin1}, Mapk8 (mitogen-activated protein kinase 8) [NCBI Gene 116554] {aka JNK}, Mpo (myeloperoxidase) [NCBI Gene 17523] {aka mKIAA4033}, Lipg (lipase G, endothelial type) [NCBI Gene 16891] {aka 3110013K01Rik, EL, lipase, mEDL}, Src (SRC proto-oncogene, non-receptor tyrosine kinase) [NCBI Gene 83805], Akt1 (AKT serine/threonine kinase 1) [NCBI Gene 24185] {aka Akt}, Akt3 (Akt serine/threonine kinase 3) [NCBI Gene 23797] {aka D930002M15Rik, Nmf350}, Akt2 (Akt serine/threonine kinase 2) [NCBI Gene 11652] {aka 2410016A19Rik, PKB, PKBbeta}, Il6 (interleukin 6) [NCBI Gene 24498] {aka ILg6, Ifnb2}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Alb (albumin) [NCBI Gene 24186] {aka Alb1, Albza}, Pik3cb (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta) [NCBI Gene 85243], Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Egfr (epidermal growth factor receptor) [NCBI Gene 24329] {aka ERBB1, ErbB-1, Errp}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Ephb1 (Eph receptor B1) [NCBI Gene 24338] {aka Ephb2, Erk, elk}, Tp53 (tumor protein p53) [NCBI Gene 24842] {aka Trp53, p53}, Fos (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 314322] {aka c-fos}, Mapk14 (mitogen activated protein kinase 14) [NCBI Gene 81649] {aka CRK1, CSBP, CSPB1, Csbp1, Csbp2, Exip}, Bcl2 (BCL2, apoptosis regulator) [NCBI Gene 24224] {aka Bcl-2}, Tnf (tumor necrosis factor) [NCBI Gene 24835] {aka RATTNF, TNF-alpha, Tnfa}, Tlr4 (toll-like receptor 4) [NCBI Gene 29260], Arg2 (arginase 2) [NCBI Gene 29215], Cd68 (CD68 antigen) [NCBI Gene 12514] {aka Lamp4, Scard1, gp110}
- **Diseases:** pain (MESH:D010146), hepatic damage (MESH:D056486), necrosis (MESH:D009336), AP (MESH:D010195), edema (MESH:D004487), insulin resistance (MESH:D007333), inflammation (MESH:D007249), inflammatory pancreatic disease (MESH:D010182), abdominal pain (MESH:D015746), obese (MESH:D009765), acute (MESH:D000208), organ damage (MESH:D000092124), acute liver injury (MESH:D017114), organ failure (MESH:D009102), colitis (MESH:D003092), toxicity (MESH:D064420), pancreatic necrosis (MESH:D019283)
- **Chemicals:** paraformaldehyde (MESH:C003043), lipids (MESH:D008055), DCFH-DA (MESH:C029569), SDS (MESH:D012967), ROS (MESH:D017382), -P (MESH:D010758), Propidium Iodide (MESH:D011419), DMSO (MESH:D004121), Linarin (MESH:C008282), PBS (MESH:D007854), CO2 (MESH:D002245), caerulein (MESH:D002108), streptomycin (MESH:D013307), PVDF (MESH:C024865), PI (MESH:D010716), DAPI (MESH:C007293), hematoxylin (MESH:D006416), penicillin (MESH:D010406), flavonoid (MESH:D005419), Calcein Acetoxymethylester (MESH:C085925), MK-2206 (MESH:C548887), 740 Y-P. (-), DAB (MESH:C000469), citrate (MESH:D019343), H2O2 (MESH:D006861)
- **Species:** C. japonicum [taxon 231009], Curcuma longa (turmeric, species) [taxon 136217], Mus musculus (house mouse, species) [taxon 10090], Artemisia capillaris (species) [taxon 265783], Homo sapiens (human, species) [taxon 9606], Chrysanthemum indicum (species) [taxon 146995]
- **Mutations:** F12K
- **Cell lines:** AR42J — Rattus norvegicus (Rat), Rat digestive system neoplasms, Cancer cell line (CVCL_0143)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12311076/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12311076/full.md

## References

11 references — full list in the complete paper: https://tomesphere.com/paper/PMC12311076/full.md

---
Source: https://tomesphere.com/paper/PMC12311076